On May 29, 2016, Einat Katzenell spoke to braintech entrepreneurs about Legal Aspects in the Early Stages of Braintech Ventures at Brainnovations – IBT’s neuroscience launchpad. Click to listen to this insightful 4-part podcast about incorporation, founders and IP.
Blog & News
After working with 8 amazing teams of braintech entrepreneurs at Brainnovations’ 2nd Cycle, we finally reached culmination of the program at Demo Day.
Check out each of the 8 teams’ impressive one-pagers inside.
Equity crowdfunding is a hot topic, and we are pleased to see that TheMarker today published Ran’s recent blog in both its print and digital versions.
נדמה שהביקורת סביב התנהלות קרן הגשמה מתעלמת מהאינטרס הכל כך מהותי – לאפשר למשק לצמוח ולהתקדם באמצעות שיטות מימון אשר אינן דורשות פרסום תשקיף והצעה לציבור לפי חוק ניירות ערך. שיטת הגיוס ״עד 35״ חוקית ותמשיך להיות איתנו לפחות עד שיכנסו לתוקף התקנות המסדירות מימון המונים.
It has just been announced that Belgian company IBA (Ion Beam Applications S.A.), a provider of proton therapy solutions for the treatment of cancer, is leading a round of capital investment in HIL Applied Medical, Ltd. (HIL), a private Israeli developer of laser-based proton therapy systems.
רשות ניירות ערך והעומד בראשה רוצים לראות במימון המונים צעד ראשון של חברות צעירות במסלול ההון שמוביל אל הבורסה. אנו מציעים לבחון אפשרות של זקיפת הון שגויס במימון המונים לטובת קריטריון הסכום המזערי של הבורסה.
“Whereas” clauses carry declarative and commercial value, as well as legal implications on the contracting parties in the event of a dispute down the road. It is therefore important to give them due consideration in advance in order to avoid and avoid unnecessary obstacles later on.
We are pleased to announce our firm has been recognized by BDi CODE 2016 in 5 distinct categories: M&A, Hi-Tech, Capital Markets, International Transactions and IP.
Recent amendments to the Companies Regulations published in April 2016 set forth that companies listed for trade on NASDAQ, NYSE or AMGX that meet certain criteria can be exempt from the requirement to appoint external directors, as generally required from public Israeli companies.
Congratulations to our client Vonetize for a successful IPO! We are also proud of our own team for having played a crucial role in the first Tel Aviv Stock Exchange IPO for 2016.
Our client SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, announced that it has entered into definitive agreements to sell shares of its common stock and warrants to purchase shares of its common stock for aggregate gross […]
Today we hosted a seminar on the exciting topic of equity crowdfunding. Over the years our firm has gained a reputation for pioneering new legal practices that have developed from technological advance, and we are very proud of our deep involvement with the exciting new realm of equity crowdfunding.
כיזמים וכמנהלים תשמעו הרבה על Lean Start-Up, ועל Agile, על Go to Market ועל Crossing the Chasm, אבל אף אחד לא יסביר לכם מה לעשות כשהכסף נגמר והשקעת המשך אינה נראית באופק. כולם רוצים לדבר על החלום – מעט מאוד מוכנים לשמוע על שברו. אבל המידע הזה חשוב. מאוד. במיוחד על רקע הבועה המסתמנת בענף ההון-סיכון, כפי שעמד עליה לאחרונה המשקיע המפורסם ביל גורלי.
It has just been announced that iGO developer NNG has acquired our client – automotive cyber startup Arilou Technologies. Arilou’s technology is designed to prevent a remote takeover of the car’s computerized systems (multimedia and locking systems, for example) that could enable a burglar to open the car’s locks, turn off the motor, and even disconnect the brakes.
It’s extremely unfortunate, but the sad reality is that startups often close down when founders experience a falling out. When I step in, my goals are to offer tools and solutions that will enable the company to continue operations seamlessly, mitigate loss of value, and when possible – help the parties separate on amicable terms enabling the founders to maintain their good reputation and continue doing business freely in this small industry.
גיוס הון באמצעות מימון המונים דורש מבנים משפטיים אשר מסוגלים להתמודד עם פלטפורמה שהיא מעין בורסה אבל היא לא בדיוק בורסה, עם מבנה האחזקות חדש שטרם נוסה, ועם מארג התקשרויות פלטפורמה-חברה וחברה-משקיעים מאתגר בלשון המעטה. מימון המונים זה שם גדול להרבה דברים. יש מימון המונים לתגמול ומכירה מוקדמת, יש מימון המונים של תרומות ויש מימון המונים לגיוס חוב (הלוואות). כעת אנו מכינים את הקרקע לשלב הבא. זה עולם חדש שנפתח ואנחנו גאים בחלקנו בפיתוח הכלים המשפטיים אשר מאפשרים לזה לקרות.
It has just been announced that our client HIL Applied Medical Ltd. has acquired US-based Nanolabz Inc. en route to developing advanced cancer radiotherapy systems. Read the PR here and on Globes here.
When the money runs out, and obligations outweigh assets, most companies, failing to locate an “angel” to save the business, will face liquidation and most likely settle for peanuts with the sale of any IP and activity to the highest bidder. It is however our experience this does not necessarily have to be the case.
Including milestones in commercial agreements enables us to set expectations between the engaging parties and link compensation to achievements. We advise our clients who are contemplating the use of milestones not to fall for their seemingly straightforward appearance, and to take the time to consider potential issues that may arise down the road.
Yesterday marked the kickoff of the 2nd cycle of Brainnovations – IBT’s braintech accelerator. For the next 4 months the 8 teams will work with the Brainnovation’s partners, mentors and team, to bring their ventures to the next level, whether in terms of financing, product definition, market definition, regulatory aspects, intellectual property issues, building a […]
ישנו קושי להעריך את תוחלת הנזק בכל הקשור לאירועי סייבר. מלבד לנזקים הישירים, מתלווים גם נזקים משפטיים משניים. הבשורה הטובה היא כי ישנם דרכים פשוטות יחסית שבהן יכול התאגיד לנקוט כדי להקטין את החשיפה לאירוע סייבר ובכלל זה את החשיפה המשפטית. בפן המעשי הדירקטוריון יכול לנקוט במספר צעדים וחשוב כי התהליך ילווה ביועצים מתאימים בתחום הסייבר, המשפט והממשל התאגידי.
Our representation of eyeSight Technologies in its $20M investment from Kuang-Chi was acknowledged on Yahoo! Finance. Once again we are proud of our team for pulling together and getting the deal done. Read about the transaction on Globes.
פעם חברות טכנולוגיה חשבו ששוק ההון גדול עליהם, בסגנון מה יש לסטארט אפ מיוקנעם לחפש ברחוב אחד העם (כיום אחוזת בית). כיום יש כבר יותר מקומץ חברות טק צעירות אשר נסחרות בתל אביב ואנו מקווים שהמגמה תתחזק. לדעתי, במקרים מסוימים, שוק ההון עשוי להיות עדיף על משקיע פרטי. אמנם חברות ציבוריות נדרשות להוצאות גדולות יותר לעומת חברות פרטיות, וחברה ציבורית גם מחייבת יותר תשומות ניהוליות, אך הניסיון מראה כי לעלות זו נלווים יתרונות רבים, וכמה מהם, בקיצור, להלן.
We are very proud of our client, eyeSight Mobile Technologies, for closing a $20,000,000 strategic transaction with Kuang-Chi Science, and being the first investment made by Kuang-Chi through its new fund in Israel. Gideon Shmuel – congratulations on this major achievement. It’s been a pleasure working with the team on this transaction. Read the press on […]
ביום ראשון הקרוב 10/4 יעלו צפונה עורכי הדין רן דימנט וזיו קינן ממשרדנו להרצות ב-Start Up North על הנושא החם של גיוס הון באמצעות מימון המונים. למעוניינים קישור להרשמה: http://tinyurl.com/jsz4hta
The tender offer mechanism is designed to prevent a situation where control of a public company is acquired without sharing the financial value of control with the other shareholders.
This week saw a public takeover bid for one of the few TASE companies that does not have a controlling shareholder, which happened to involve one of our clients, making it a perfect occasion to briefly explain the logic behind tender offers.
לאחרונה פרסמה רשות ניירות ערך טיוטת תקנות אשר יסדירו את הנושא החם של השקעות הון באמצעות פלטפורמה של מימון המונים, בהמשך להמלצות הועדה לקידום השקעות בחברות ציבוריות הפועלות בתחום המחקר והפיתוח. מטרת מנגנון זה, בין היתר, לאפשר לחברות היי-טק צעירות אשר אינן מתאימות להירשם בבורסה לגייס סכומים קטנים יחסית של כסף ממספר גדול של משקיעים ללא צורך בפרסום תשקיף. במילים פשוטות, לאחר פרסום התקנות, חברות צעירות יוכלו לגייס הון באמצעות מימון המונים בתמורה למניות (להבדיל ממוצרים שהחברה מוכרת), מבלי לפרסם תשקיף, מבלי להירשם בבורסה ומבלי להיות כפופות לרגולציה מכבידה אשר חלה על חברות ציבוריות מכוח חוק ניירות ערך וחוק החברות.
KATZENELL DIMANT is proud to be an official supporter of Fresh Paint Contemporary Art Fair, Tel Aviv, the largest and most influential annual art event in Israel, attracting over 30,000 visitors every year. We have been supporting Fresh Paint for the past 7 years, holding true to our belief in the importance of promoting Israeli art and culture. From the Fresh […]
While other areas of high technology categorically take a B2B or B2C approach to marketing, Braintech doesn’t quite fit the common rubric. Consider the identity of your customers (the who) and the means by which they’re going to pay for your product (the how) – it’s plain to see that neurotechnology is in a class of its own.
Resolving the who and how issues at the very early stages of development is critical, because even though achieving scientific validation is fantastic – proving something works doesn’t in and of itself mean that it can be commercialized.
While serial entrepreneurs may already be immune, or at the very least indifferent, first-timers often have trouble biting the Repurchase Agreement bullet. How did you feel when your investors told you that reverse-vesting provisions were going to apply to shares that were already yours?
בהיעדר הגנה הרמטית כנגד התקפות סייבר, אימוץ תכנית היערכות לאירועי סייבר תסייע לגדר את הסיכון ולצמצם את החשיפה של החברה ושל מנהליה להליכים משפטיים לאחר אירוע סייבר. הליכים משפטיים אלה, על אחת כמה וכמה בחברה ציבורית המחזיקה מידע פנים, הם צפויים וניתן להיערך אליהם בעוד מועד.
When presenting your startup to potential investors, there are two advantages available under Israeli law that you might want to emphasize, which could make investing in your startup much more attractive, particularly at the seed and pre-seed stages.
The first advantage is the tax benefits under the “Angels Law”, and the second is the $1:$1 grant under the “early stage companies” OCS program.
It’s that time of year again, so for those of you who might have missed it, here’s the message we share with potential candidates: Our interns are significant members of our legal team and play a vital role in all areas of the firm’s professional activity. Our interns benefit greatly from being part of a boutique firm, […]
While the reverse IPO may impose the stigma of “not being good enough”, and ultimately being more costly than taking Main Street– there are some very strong arguments in favor of the “back door”, mostly obvious but some only known to experienced players in this field.
while cybersecurity entrepreneurs might have it relatively easy convincing Angels and VCs of their business opportunity, viability, and immediate need and market size, they’re having the hardest time finding qualified employees to take their ideas forward.
Mature companies typically have mechanisms in place designated to monitor and control ESO grants, but when founders are bootstrapping they tend to do things absent-mindedly.
Some classic examples of ESO grant mistakes include: forgetting to set an exercise price; failing to define vesting or exercise periods; omitting an expiry date; committing to specific tax treatment; and – the BIG one you’ve been waiting for, promising a percentage of the company rather than a specific number of shares.
Brainnovations is a unique accelerator program that provides tailored education, mentoring and support to early stage projects in the brain space. For the duration of the program participants receive one-on-one consultations and support from world class mentors, are guided by industry experts on the ins and outs of establishing a life science startup, and gain access to IBT’s extensive network of opinion leaders, research institutions and investors and more.
KATZENELL DIMANT has been recognized as one of Israel’s top law firms for 2015 by Globes Dun’s 100 in 4 (!) distinct categories: international transactions, capital markets, hi-tech & mergers and acquisitions, with similar accolades from BDi CODE. What did we do to deserve the honour? 15 M&A transactions valued at over NIS 3 billion 80 financing rounds totalling NIS 1.05 billion […]
KATZENELL DIMANT represents Multiphy Ltd. in an $8.5 million financing round led by strategic partners and VCs.
KATZENELL DIMANT represents Kitov Pharmaceuticals Holdings Ltd. in publishing a prospectus for public issuance of rights to purchase its securities and registration of such securities for trade on the Tel Aviv Stock Exchange. Kitov Pharmaceuticals is an innovative biopharmaceutical company focused on late-stage drug development.
KATZENELL DIMANT continues to support Fresh Paint, including in connection with the annual Fresh Paint Fair, promoting new artists and designers with a purpose to make plastic art more available to the public, meeting the increasing demand from art lovers, lovers of design and collectors to purchase original and innovative art works. From the official website: […]
We are pleased to announce that our partners Einat Katzenell and Ran Dimant have been ranked in the 2015 edition of BDi coface.
KATZENELL DIMANT partners with Israel Brain Technologies (IBT) for the establishment of Brainnovations, a Braintech Launchpad for support of early stage projects in the Braintech industry.
KATZENELL DIMANT represents the shareholders of TradeFX Limited in the sale of a majority of their shares to Playtech plc (LSE:PTEC) for €208,000,000 and earnout payments of up to an additional €248,000,000. The firm represented the shareholders in the negotiation and drafting of the transaction documents, preparation of the disclosure schedule and closing of the deal. […]
KATZENELL DIMANT represents SteadyMed Ltd. in its Nasdaq IPO: on March 25, 2015, the company announced the closing of its initial public offering of 4,700,000 ordinary shares at a price to the public of $8.50 per share, resulting in gross proceeds of approximately $40,000,000 before underwriting discounts and commissions.
Dun & Bradstreet’s Globes Dun’s 100, one of Israel’s leading legal directory, ranks KATZENELL DIMANT’s Hi-Tech and Capital Markets among the leading practices in Israel in these fields.
Braintech 2015 to take place on March 11-12, 2015 in the Port of Tel Aviv. KATZENELL DIMANT has partnered with Israel Brain Technologies (IBT) since its inception and is supporting the first ever conference to take place in Israel for promoting the BrainTech industry, and is expected to include worldwide players in this industry, including global […]
Katzenell Dimant represents Agri Invest Ltd. in a transaction for the sale of the control in the company, for the purpose of purchase of all shares of Cofix Ltd. (reverse merger) by Agri.
KATZENELL DIMANT represents Kitov Pharmaceuticals Holdings Ltd. (NASDAQ/TASE:KTOV) in several shelf offerings of its securities to the public. Kitov Pharmaceuticals is an innovative biopharmaceutical company focused on late-stage drug development.
KATZENELL DIMANT represents Technoplus Ventures Ltd. in publishing a shelf prospectus for public offering of its securities, and in registration of such securities for trade on the Tel Aviv Stock Exchange.
KATZENELL DIMANT represents Nextgen Biomed Ltd. (TLV: NXGN) in several shelf offerings of its securities to the public. Nextgen-Biomed is a phase II/III public company developing novel topical, steroid-free treatments for the growing market of psoriasis.
KATZENELL DIMANT represents Harel Sal Ltd., an issuer of exchange traded notes (ETNs) and financial products, in its issuance of 10 exchange traded notes. Harel Sal is a wholly owned subsidiary of Harel Insurance Investments and Financing and is engaged in issuing complex financial products including ETNs, covered warrants and various structures. Harel Sal manages over 80 ETN’s, Shorts […]
KATZENELL DIMANT represents HIL Applied Medical Ltd. in two financing rounds, totalling approximately US$ 1.2 million and led by OurCrowd.
KATZENELL DIMANT represents the seller of Marmar Media Ltd. shares in a transaction for sale of a majority of the shares held by it to XLMedia plc for an amount of up to US$7,360,000. The firm represented the seller in the negotiation and drafting of the transaction documents, preparation of the disclosure schedule and closing of the […]
KATZENELL DIMANT represents eyeSight Mobile Technologies Ltd. in financing rounds totaling approximately $ 7 million, led by foreign investors
KATZENELL DIMANT represents Inventech Central Hotels Ltd., publicly traded on the Tel Aviv Stock Exchange, in connection with the Company’s creditors arrangement under Section 350 of the Israeli Companies Ordinance, and in acquisition of the control of the company by Inbal Or Group.
KATZENELL DIMANT represents Market Tech Holdings Ltd., a public company traded on the AIM, in acquiring StuccoMedia Ltd., an Israeli company with a proprietary e-commerce platform,for US$34,500,000 plus an additional contingent payment of US$8,000,000. Market Tech owns and manages London’s famous Camden Market. The firm represented the client in the Israeli due diligence and in […]
KATZENELL DIMANT represents SafeCharge International Group Limited, a public company traded on the AIM, in the acquisition of CreditGuard Ltd. for NIS 30,000,000. The firm represented SafeCharge in the due diligence process, the negotiations of the terms of the transaction, the drafting of all transaction documents and eventually the closing of the deal.
KATZENELL DIMANT represents SteadyMed Ltd. in a $30 million financing round led by US hedge funds and investments funds and private investors.
Katzenell Dimant represents a foreign company in the purchase of the assets of Vidmind Ltd., an Israeli company under temporary liquidation. The firm submitted the client’s bid, negotiated with the Temporary Liquidator and closed the purchase and follow-up legalities.
Katzenell Dimant represents Spondoolies Tech Ltd. in two financing rounds totaling to approximately US$ 12 million, led by the existing and new investors in the company.
Katzenell Dimant represents Crossrider plc, a public company traded on the AIM, in the purchase of all shares of Definiti Media Ltd. and all assets of Adjilion Max Ltd. (a company associated with Definiti), in the total amount of $12,000,000. We represented Crossrider in the due diligence process, the negotiations of the terms of the transactions, […]
Katzenell Dimant represents Agri Invest Ltd., a public company traded on the Tel Aviv Stock Exchange (TLV:AGRI) in a licensing and cooperation agreement with Hadasit, the Technology Transfer Company of Hadassah Medical Organization.
Katzenell Dimant represents a health institution in a major asset sale transaction with one of the country’s largest health institution.
Katzenell Dimant represents Kitov Pharmaceuticals Holdings Ltd. (NASDAQ/TASE:KTOV) in the publication of a shelf prospectus for the issuance to the public of its securities and registration of such securities for trade of TASE, and in a shelf offering of its securities under such shelf prospectus.
Katzenell Dimant represents Capital Point Ltd. (TLV:CPTP) in a pre-IPO financing agreement with Check-Cap, in which Capital Point Ltd. and other investors provided Check-Cap with financing and a line of credit in an amount of up to US$ 12,000,000.
Katzenell Dimant represents iAngels, a platform for crowd funding by equity investments in high-tech companies, in connection with the various corporate structures, specific investments etc.
Katzenell Dimant acts as the Israeli counsel of Crossrider plc in the initial public offering of the company’s shares on the AIM.
Katzenell Dimant represents Harel Sal Ltd. in the issuance of 31 exchange traded notes. Harel Sal is an issuer of exchange traded notes and financial products (wholly owned subsidiary of Harel Insurance Investments and Financial Services Ltd.), that engages in issuing complex financial products including exchange traded notes (ETN’s), covered warrants, and other structures. Harel Sal manages […]
Katzenell Dimant represents Capital Point Ltd. (TLV:CPTP) in several private placements and shelf offerings of its securities to the public.
Katzenell Dimant acts as the Israeli lawyers of Safecharge International Group Limited in the initial public offering of the company’s shares on the AIM.
Katzenell Dimant represents Neaten Biomed Ltd. in publishing a prospectus for the issuance to the public of rights to purchase its securities and registration of such securities for trade of TASE, and in a shelf offering of its securities under such shelf prospectus.
Katzenell Dimant represents Capital Point Ltd. (TLV:CPCP) in an investment agreement with Noiroderm Ltd., in which Capital Point Ltd. and external investors invested in Noiroderm Ltd., by way of convertible loan, a total of US$ 18 million.
Katzenell Dimant represents Nextgen Biomed Ltd. (TLV:NXGN) , a public Company traded on TASE, in several private debt and capital financing rounds.
We area pleased to announce that Katzenell Dimant has been ranked in the 2014 edition of BDi CODE legal guide in 3 distinct practice areas – Hi-Tech, Capital Markets, and Mergers & Acquisitions.
Katzenell Dimant represents Kitov Pharmaceuticals Holdings Ltd. a public company traded on TASE, in a cooperation and investment agreement with Dexcel Pharma Ltd., with respect to the manufacture of the pharmaceuticals product developed by Kitov and certain rights regarding the distribution of such product. Read the press on Globes here.
Katzenell Dimant represents Maayan Ventures Ltd. in negotiations for a debt settlement with Company’s bondholders. The settlement included a settlement of Maayan with its creditors, including holders of bonds publicly traded on TASE, in an amount of approximately NIS 40,000,000.
Katzenell Dimant represents Partam High Tech Ltd., a venture capital investment arm, in its engagement with Nielsen Innovation in connection with its incubator located in Caesarea.
Katzenell Dimant represents APM Automation Solutions Ltd. in its sale to Emerson Electric. The firm continues to represent APM (being Emerson Israel) after the acquisition and deems this as a great vote of confidence by Emerson International.
Braintech 2013 takes place on October 14-15, 2013 in Tel Aviv. Katzenell Dimant has partnered with Israel Brain Technologies (IBT) since its inception, and is supporting the conference, the first of its kind in Israel for promotion of the braintech industry, and is expected to attract worldwide players in this industry, including global companies, venture capital investors, […]
Katzenell Dimant represents Mainrom, a public Company traded on TASE in its acquisition (reverse merger) of Kitov Pharmaceuticals Inc. (“Kitov”), in which Kitov’s shareholders sold 100% of their shareholdings in Kitov in exchange for shares of the Company.
Katzenell Dimant represented Hairstetics in a US$ 3 million financing round led by Pontifax and Allegro (the investment arm of Generali). Hairstetics is developing an automated, non-surgical device for synthetic hair transplantation.